These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10636172)

  • 1. Remission of HIV myelopathy after highly active antiretroviral therapy.
    Staudinger R; Henry K
    Neurology; 2000 Jan; 54(1):267-8. PubMed ID: 10636172
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal of AIDS dementia after combination therapy with stavudine, lamivudine, and nelfinavir.
    Mastroianni CM; Trinchieri V; Santopadre P; Lichtner M; Forcina G; D'Agostino C; Dell'Isola S; Vullo V
    J Neurol; 1999 Oct; 246(10):972-3. PubMed ID: 10552250
    [No Abstract]   [Full Text] [Related]  

  • 3. Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir.
    Anderson RD
    Antivir Ther; 1998; 3 Suppl 4():63-4. PubMed ID: 10723514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission of HIV-associated myelopathy after highly active antiretroviral therapy.
    Fernández-Fernández FJ; de la Fuente-Aguado J; Ocampo-Hermida A; Iglesias-Castañón A
    J Postgrad Med; 2004; 50(3):195-6. PubMed ID: 15377804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe HIV-associated thrombocytopenia despite effective highly active antiretroviral therapy in a vertically infected child.
    Ndagijimana JM; Kroll H; Niehues T
    AIDS; 2002 Mar; 16(5):802-3. PubMed ID: 11964543
    [No Abstract]   [Full Text] [Related]  

  • 6. Induction-maintenance (5 --> 3 drugs) in HIV-infected patients with high viral load.
    Soriano V; Barreiro P; Gonzalez-Lahoz J
    AIDS Patient Care STDS; 2000 Nov; 14(11):573-4. PubMed ID: 11155897
    [No Abstract]   [Full Text] [Related]  

  • 7. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are nelfinavir-containing regimens effective as second-line triple therapy?
    Bernasconi E; Magenta L; Piffaretti JC; Carota A; Moccetti T
    AIDS; 2000 Jan; 14(1):95-6. PubMed ID: 10714576
    [No Abstract]   [Full Text] [Related]  

  • 9. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
    Roca B; Gómez CJ; Arnedo A
    J Infect; 2000 Jul; 41(1):50-4. PubMed ID: 10942640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.
    Maserati R; Villani P; Seminari E; Pan A; Lo Caputo S; Regazzi MB
    AIDS; 1999 May; 13(7):870-1. PubMed ID: 10357395
    [No Abstract]   [Full Text] [Related]  

  • 11. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HIV effects of nelfinavir reported after ten months of combination therapy.
    AIDS Patient Care STDS; 1997 Aug; 11(4):289-90. PubMed ID: 11361848
    [No Abstract]   [Full Text] [Related]  

  • 14. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
    Bongiovanni M; Chiesa E; Monforte Ad; Bini T
    Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.
    Wiznia A; Stanley K; Krogstad P; Johnson G; Lee S; McNamara J; Moye J; Jackson JB; Mendez H; Aguayo R; Dieudonne A; Kovacs A; Bamji M; Abrams E; Rana S; Sever J; Nachman S
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1113-21. PubMed ID: 10954886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Too little of a good thing.
    Friedland GH; Gulick RM
    AIDS Clin Care; 1998 Oct; 10(10):76-7. PubMed ID: 11365860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nelfinavir - major trial results at retroviruses conference.
    AIDS Treat News; 1997 Feb; (No 265):3-4. PubMed ID: 11364240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of nelfinavir in HIV-1-infected children.
    van Heeswijk RP; Scherpbier HJ; de Koning LA; Heymans HS; Lange JM; Beijnen JH; Hoetelmans RM
    Ther Drug Monit; 2002 Aug; 24(4):487-91. PubMed ID: 12142631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.